Limits...
Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms.

Lee D, Wilson K, Akehurst R, Cowie MR, Zannad F, Krum H, van Veldhuisen DJ, Vincent J, Pitt B, McMurray JJ, Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF) Stu - Heart (2014)

Bottom Line: The present study evaluated the cost-effectiveness of eplerenone in the treatment of these patients in the UK and Spain.Probabilistic sensitivity analysis suggested a 100% likelihood of eplerenone being regarded as cost-effective at a willingness-to-pay threshold of £20 000 per QALY (UK) or €30 000 per QALY (Spain).By currently accepted standards of value for money, the addition of eplerenone to optimal medical therapy for patients with chronic systolic HF and mild symptoms is likely to be cost-effective.

View Article: PubMed Central - PubMed

Affiliation: BresMed, Sheffield, UK.

Show MeSH

Related in: MedlinePlus

Model structure. CV, cardiovascular; HF, heart failure; QALY, quality-adjusted life year.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4215293&req=5

HEARTJNL2014305673F1: Model structure. CV, cardiovascular; HF, heart failure; QALY, quality-adjusted life year.

Mentions: A discrete-event simulation model was developed to project the rates and times of important clinical events and assign to these lifetime costs and quality-of-life consequences (figure 1). Two treatment pathways were simulated, in line with the trial protocol: standard therapy with the addition of eplerenone (starting dose of 25 mg once daily; at 4 weeks, increased to 50 mg once daily) and standard therapy with no additional active treatment (standard care). Model outputs are presented in terms of mean life expectancy, quality-adjusted life expectancy, direct costs and incremental cost-effectiveness ratios (ICERs).


Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms.

Lee D, Wilson K, Akehurst R, Cowie MR, Zannad F, Krum H, van Veldhuisen DJ, Vincent J, Pitt B, McMurray JJ, Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF) Stu - Heart (2014)

Model structure. CV, cardiovascular; HF, heart failure; QALY, quality-adjusted life year.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4215293&req=5

HEARTJNL2014305673F1: Model structure. CV, cardiovascular; HF, heart failure; QALY, quality-adjusted life year.
Mentions: A discrete-event simulation model was developed to project the rates and times of important clinical events and assign to these lifetime costs and quality-of-life consequences (figure 1). Two treatment pathways were simulated, in line with the trial protocol: standard therapy with the addition of eplerenone (starting dose of 25 mg once daily; at 4 weeks, increased to 50 mg once daily) and standard therapy with no additional active treatment (standard care). Model outputs are presented in terms of mean life expectancy, quality-adjusted life expectancy, direct costs and incremental cost-effectiveness ratios (ICERs).

Bottom Line: The present study evaluated the cost-effectiveness of eplerenone in the treatment of these patients in the UK and Spain.Probabilistic sensitivity analysis suggested a 100% likelihood of eplerenone being regarded as cost-effective at a willingness-to-pay threshold of £20 000 per QALY (UK) or €30 000 per QALY (Spain).By currently accepted standards of value for money, the addition of eplerenone to optimal medical therapy for patients with chronic systolic HF and mild symptoms is likely to be cost-effective.

View Article: PubMed Central - PubMed

Affiliation: BresMed, Sheffield, UK.

Show MeSH
Related in: MedlinePlus